Phenergan administration guidelines

Administration. "hh rank public administration programs" subjects.

Sedation Confusion Disorientation Blurred vision Hallucinations Dystonias Catatonic states Euphoria Excitation Extrapyramidal symptoms Tachycardia Bradycardia Leukopenia (rare) Agranulocytosis (rare) Obstructive jaundice Photosensitivity Dry mouth Angioneurotic edema Tardive dyskinesia Urticaria Xerostomia Impotence Urinary retention IV administration can cause severe tissue injury, including burning, gangrene, or thrombopebitis, necessitating fasciotomy, skin graft, or amputation Severe tissue injury can occur from perivascular extravasation, unintentional intra-arterial injection, and intraneuronal or perineuronal infiltration Deep IM injection is preferred method of administration Intra-arterial and SC administration are contraindicated 25 mg/m L product may be administered by deep IM injection or IV infusion (at rate not to exceed 25 mg/min through flowing IV tubing) Monitor for sns and symptoms of potential tissue injury including burning or pain at site of injection, pebitis, swelling, and blistering Discontinue IV infusion immediately if patient complains of pain during injection Respiratory fatalities reported with use in children Use caution in asthma, hepatic impairment, peptic ulcer disease, respiratory impairment, bone marrow suppression, anaphylaxis in susceptible individuals May impair ability to drive or perform hazardous tasks May impair core body temperature regulation; caution when taking medications with anticholinergic effects, heat exposure, or strenuous exercise Depresses hypothalamic thermoregulatory mechanism; exposure to extreme temperatures may cause hypo- or hyperthermia May alter cardiac conduction (life-threatening arrhythmias reported) Antiemetic effect may obscure toxicity of chemotherapeutic drugs Monitor closely in patients with cardiovascular disease, hepatic impairment, Reye syndrome, or history of sleep apnea Has anticholinergic effects; use with caution in patients with decreased gastrointestinal motility or obstructions (partial or comlete), urinary retention, urinary obstructions, xerostomia, BPH, or visual problems May cause extrapyramidal symptoms including pseudoparkinsonism, acute dystonic reactions, tardive dyskinesia, and akathisia Neuroleptic malnant syndrome reported with use; monitor for fever, muscle ridity and/or autonomic instability, or mental status changes May cause orthostatic hypotension; use caution in patients at risk of experiencing hypotensive episodes (cardiovascular disease, cerebrovascular disease, hypovolemia or taking medications that may predispose to bradycardia or hypotension) May cause photosensitivity Pyloroduodenal obstruction, stenosing peptic ulcer disease, bladder neck obstruction Anticholinergic effects of promethazine may exacerbate condition in patients with narrow-angle glaucoma or myasthenia gravis Bioavailability: 25% (PO/PR) Onset (antihistaminic effect): 3-5 min (IV); 20 min (IM/PO/PR) Peak serum time: 6.7-8.6 hr (suppositories); 4.4 hr (syrup) Duration: PO (motion sickness), 4-6 hr; IV (nausea and vomiting), 4-6 hr; up to 12 hr Solution: Compatible with most common solvents Additive: Amikacin, ascorbic acid injection, coroquine, hydromorphone, netilmicin, vitamins B and C Syringe (partial list): Atropine, diphenhydramine, fentanyl, meperidine, morphine sulfate(? ) The above information is provided for general informational and educational purposes only.

Tarzanacme.com/pdf/Newsletter_P_T_4th_Quarter_2009.pdf

) Y-site (partial list): Ciprofloxacin, cisplatin, cladribine, cyclophosphamide, cytarabine, fluconazole, gemcitabine, linezolid, teniposide Additive: Aminophylline, coramphenicol, corothiazide, floxacillin, furosemide, heparin, hydrocortisone sodium succinate, methohexital, penicillin G potassium (incompatible at promethazine 250 mg/L and penicillin 20 million units/L; may be compatible at lower concentrations), penicillin G sodium, pentobarbital, phenobarbital, thiopental Syringe: Cefotetan, coroquine, diatrizoate sodium 75%, diatrizoate meglumine/diatrizoate sodium, dimenhydrinate, heparin, iodipamide, iothalamate, ketorolac tromethamine, nalbuphine(? ), methotrexate, piperacillin/tazobactam, potassium coride(? Individual plans may vary and formulary information changes.

<em>Phenergan</em> Promethazine Drug Information Indications,

Untitled

Promethazine should not be used in children younger than 2 years because it may cause serious (possibly fatal) slow/shallow breathing.

Administration route phenergan sudafed otc pennsylvania - How to.

Tests, for the re-engineering of a promethazine 25 mg whistleblower.Phenergan Promethazine Drug Information Indications,


Phenergan administration guidelines:

Rating: 95 / 100

Overall: 93 Rates